520 related articles for article (PubMed ID: 14697445)
21. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L
Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459
[TBL] [Abstract][Full Text] [Related]
22. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
[TBL] [Abstract][Full Text] [Related]
23. Postoperative hypofractionated radiotherapy in glioblastoma multiforme.
Arslan M; Karadeniz AN; Aksu G; Güveli M; Fayda M; Doğan AK; Akyüz F
J BUON; 2006; 11(1):39-42. PubMed ID: 17318950
[TBL] [Abstract][Full Text] [Related]
24. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
25. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.
Kitamura K; Shirato H; Shinohara N; Harabayashi T; Onimaru R; Fujita K; Shimizu S; Nonomura K; Koyanagi T; Miyasaka K
Cancer J; 2003; 9(4):268-76. PubMed ID: 12967137
[TBL] [Abstract][Full Text] [Related]
26. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.
Tsien C; Moughan J; Michalski JM; Gilbert MR; Purdy J; Simpson J; Kresel JJ; Curran WJ; Diaz A; Mehta MP;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):699-708. PubMed ID: 18723297
[TBL] [Abstract][Full Text] [Related]
27. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme.
Monjazeb AM; Ayala D; Jensen C; Case LD; Bourland JD; Ellis TL; McMullen KP; Chan MD; Tatter SB; Lesser GJ; Shaw EG
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):743-8. PubMed ID: 21236604
[TBL] [Abstract][Full Text] [Related]
28. Hypofractionated conformal irradiation of patients with malignant glioma.
Aboziada MA; Abo-Kresha AE
J Egypt Natl Canc Inst; 2012 Sep; 24(3):139-43. PubMed ID: 22929920
[TBL] [Abstract][Full Text] [Related]
29. Acute toxicity and changes in quality of life during a combined radio-chemotherapy of glioblastomas with topotecan (Hycamtin).
Gross MW; Altscher R; Brandtner M; Häusser-Mischlich H; Kiricuta IC; Siegmann AD; Engenhart-Cabillic R
Strahlenther Onkol; 2001 Dec; 177(12):656-61. PubMed ID: 11789404
[TBL] [Abstract][Full Text] [Related]
30. Hypofractionated high-dose irradiation with positron emission tomography data for the treatment of glioblastoma multiforme.
Miwa K; Matsuo M; Ogawa S; Shinoda J; Asano Y; Ito T; Yokoyama K; Yamada J; Yano H; Iwama T
Biomed Res Int; 2014; 2014():407026. PubMed ID: 24977151
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
32. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
[TBL] [Abstract][Full Text] [Related]
33. Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
Livsey JE; Cowan RA; Wylie JP; Swindell R; Read G; Khoo VS; Logue JP
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1254-9. PubMed ID: 14630259
[TBL] [Abstract][Full Text] [Related]
34. Evaluating changes in tumor volume using magnetic resonance imaging during the course of radiotherapy treatment of high-grade gliomas: Implications for conformal dose-escalation studies.
Tsien C; Gomez-Hassan D; Ten Haken RK; Tatro D; Junck L; Chenevert TL; Lawrence T
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):328-32. PubMed ID: 15890571
[TBL] [Abstract][Full Text] [Related]
35. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Dhermain F
Chin J Cancer; 2014 Jan; 33(1):16-24. PubMed ID: 24384237
[TBL] [Abstract][Full Text] [Related]
36. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
[TBL] [Abstract][Full Text] [Related]
37. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
38. Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
Massaccesi M; Ferro M; Cilla S; Balducci M; Deodato F; Macchia G; Valentini V; Morganti AG
Int J Clin Oncol; 2013 Oct; 18(5):784-91. PubMed ID: 22892797
[TBL] [Abstract][Full Text] [Related]
39. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma.
Bradley JD; Ieumwananonthachai N; Purdy JA; Wasserman TH; Lockett MA; Graham MV; Perez CA
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):49-57. PubMed ID: 11777621
[TBL] [Abstract][Full Text] [Related]
40. Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme.
Greer L; Pannullo SC; Smith AW; Taube S; Yondorf MZ; Parashar B; Trichter S; Nedialkova L; Sabbas A; Christos P; Wernicke AG
Cureus; 2017 Jun; 9(6):e1388. PubMed ID: 28775928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
